Vincerx Pharma, Inc.
VINC
$0.8145
$0.00550.68%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.24M | 11.86M | 12.06M | 13.64M | 15.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.17M | 29.99M | 34.68M | 42.61M | 50.12M |
| Operating Income | -28.17M | -29.99M | -34.68M | -42.61M | -50.12M |
| Income Before Tax | -27.03M | -28.19M | -37.94M | -40.16M | -46.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.03 | -28.19 | -37.94 | -40.16 | -46.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.03M | -28.19M | -37.94M | -40.16M | -46.47M |
| EBIT | -28.17M | -29.99M | -34.68M | -42.61M | -50.12M |
| EBITDA | -28.12M | -29.93M | -34.63M | -42.56M | -50.06M |
| EPS Basic | -22.46 | -25.90 | -35.55 | -37.76 | -43.78 |
| Normalized Basic EPS | -14.03 | -16.19 | -22.22 | -23.60 | -27.36 |
| EPS Diluted | -22.46 | -25.90 | -35.55 | -37.76 | -43.78 |
| Normalized Diluted EPS | -14.03 | -16.19 | -22.22 | -23.60 | -27.36 |
| Average Basic Shares Outstanding | 5.20M | 4.70M | 4.27M | 4.26M | 4.25M |
| Average Diluted Shares Outstanding | 5.20M | 4.70M | 4.27M | 4.26M | 4.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
